Clovis Oncology

Clovis writes a $20 million check payable to the SEC, hoping to rid itself of the lingering roci probe
Endpoints
Thu, 08/2/18 - 11:20 pm
Clovis Oncology
SEC
rociletinib
Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer
CP Wire
Fri, 04/6/18 - 02:46 pm
Clovis Oncology
Rubraca
ovarian cancer
Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer
Fri, 04/6/18 - 02:45 pm
Clovis Oncology
Rubraca
ovarian cancer
Tesaro Wants a Stronger Grip in Ovarian Cancer
Yahoo/Motley Fool
Tue, 03/27/18 - 10:10 pm
Tesaro
AstraZeneca
Clovis Oncology
ovarian cancer
Zejula
Rubraca
Lynparza
AstraZeneca Goes Up Against 2 Cancer Upstarts
Motley Fool
Sat, 03/10/18 - 09:17 am
AstraZeneca
Clovis Oncology
PARP inhibitors
Lynparza
ovarian cancer
breast cancer
Rubraca
Zejula
AstraZeneca's Lynparza Now 'King' Of Its Class — Triumphing Over Tesaro
Investors Business Daily
Sat, 02/3/18 - 09:09 am
AstraZeneca
Lynparza
Tesaro
cancer
Rubraca
Clovis Oncology
Why These 3 Biotech Stocks Could Outperform Their Peers In 2018
Investors Business Daily
Sat, 01/6/18 - 12:32 pm
biotech
Puma Biotechnology
Incyte
Clovis Oncology
3 Companies Competing to Gain Lead in Ovarian Cancer Market
Yahoo/Zacks.com
Sat, 11/25/17 - 12:35 pm
ovarian cancer
AstraZeneca
Merck
Lynparza
Rubraca
Clovis Oncology
Zejula
Tesaro
AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth
Fierce Pharma
Wed, 11/15/17 - 08:51 pm
AstraZeneca
Merck
Clovis Oncology
Tesaro
PARP inhibitors
ovarian cancer
Zejula
Rubraca
Lynparza
Clovis looks to expand label for PARP inhibitor
Biopharma Dive
Wed, 10/11/17 - 10:57 pm
Clovis Oncology
PARP inhibitors
Rubraca
AstraZeneca, Tesaro and Clovis need to slash the cost of PARP meds, watchdog says
Fierce Pharma
Mon, 10/2/17 - 10:10 pm
AstraZeneca
Tesaro
Clovis Oncology
PARP inhibitors
drug pricing
ovarian cancer
Lynparza
Zejula
Rubraca
A Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It
Forbes
Mon, 09/11/17 - 09:16 am
pancreatic cancer
PARP inhibitors
Clovis Oncology
Rubraca
ESMO17: Clovis seeking new indication on positive ARIEL3 data
BioPharma Dive
Sun, 09/10/17 - 11:32 am
ESMO
Clovis Oncology
Rubraca
ovarian cancer
Here's Why Clovis Stock Is Up Almost 60% So Far in 2017
Yahoo/Zacks.com
Thu, 08/24/17 - 09:49 am
Clovis Oncology
Rubraca
ovarian cancer
Ovarian Cancer Market Still Up For Grabs
Barron's
Sat, 08/19/17 - 10:48 am
ovarian cancer
Lynparza
Tesaro
AstraZeneca
Clovis Oncology
Why Clovis Oncology Tumbled 13.5% Today
Motley Fool
Mon, 07/31/17 - 09:58 pm
Clovis Oncology
Rubraca
Bristol-Myers Squibb
Bristol-Myers and Clovis will partner for cancer combination trials
Marketwatch
Mon, 07/31/17 - 10:07 am
clinical trials
Bristol-Myers Squibb
Clovis Oncology
Opdivo
Rubraca
Cancer-fighting PARP drugs from AstraZeneca, Clovis and Tesaro largely overpriced, watchdog says
Fierce Pharma
Thu, 07/13/17 - 09:33 pm
PARP inhibitors
AstraZeneca
Clovis Oncology
Tesaro
drug pricing
Here's Why Clovis Oncology Inc. Jumped 70% in June
Motley Fool
Fri, 07/7/17 - 08:33 am
Clovis Oncology
ovarian cancer
Rubraca
Pfizer Fueling Growth Of Competitors' Pipelines
Forbes
Tue, 06/27/17 - 10:02 am
Pfizer
R&D
Clovis Oncology
Puma Biotechnology
Bioventus
Shire
AstraZeneca

Pages